Faculty Research Interest Seminar Series Graduate School of Public Health, UNIVERSITY of PITTSBURGH Methodological Research and Collaboration Lan Kong.

Slides:



Advertisements
Similar presentations
Gatekeeping Testing Strategies in Clinical Trials Alex Dmitrienko, Ph.D. Eli Lilly and Company FDA/Industry Statistics Workshop September 2004.
Advertisements

FDA/Industry Statistics Workshop 2005 Parallel Session 6: Vaccine Trials 10:10 am – 11:30 am, Sept. 16, 2005.
A Flexible Two Stage Design in Active Control Non-inferiority Trials Gang Chen, Yong-Cheng Wang, and George Chi † Division of Biometrics I, CDER, FDA Qing.
By Trusha Patel and Sirisha Davuluri. “An efficient method for accommodating potentially underpowered primary endpoints” ◦ By Jianjun (David) Li and Devan.
Departments of Medicine and Biostatistics
Multiple Comparisons Measures of LD Jess Paulus, ScD January 29, 2013.
ODAC May 3, Subgroup Analyses in Clinical Trials Stephen L George, PhD Department of Biostatistics and Bioinformatics Duke University Medical Center.
Controlling the Experimentwise Type I Error Rate When Survival Analyses Are Planned for Subsets of the Sample. Greg Yothers, MA National Surgical Adjuvant.
Detecting an interaction between treatment and a continuous covariate: a comparison between two approaches Willi Sauerbrei Institut of Medical Biometry.
Estimation and Reporting of Heterogeneity of Treatment Effects in Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare.
Department of Biostatistics Faculty Research Seminar Series What am I doing? (Besides teaching BIOST 2083: Linear Models) Abdus S Wahed, Ph.D. Assistant.
Recursive Partitioning Method on Survival Outcomes for Personalized Medicine 2nd International Conference on Predictive, Preventive and Personalized Medicine.
Copyright (c) Li Zhu Biostatistics and Its Role in Public Health Li Zhu, PhD Assistant Professor of Biostatistics Department of Epidemiology and.
Power and Sample Size David M. Thompson, Ph.D., P.T.
1 A Bayesian Non-Inferiority Approach to Evaluation of Bridging Studies Chin-Fu Hsiao, Jen-Pei Liu Division of Biostatistics and Bioinformatics National.
Common Problems in Writing Statistical Plan of Clinical Trial Protocol Liying XU CCTER CUHK.
Rankings: What do they matter, what do they measure? Anne McFarlane August 18, 2010.
Re-Examination of the Design of Early Clinical Trials for Molecularly Targeted Drugs Richard Simon, D.Sc. National Cancer Institute linus.nci.nih.gov/brb.
Survival Analysis A Brief Introduction Survival Function, Hazard Function In many medical studies, the primary endpoint is time until an event.
Biostat Didactic Seminar Series Analyzing Binary Outcomes: Analyzing Binary Outcomes: An Introduction to Logistic Regression Robert Boudreau, PhD Co-Director.
Survival analysis Brian Healy, PhD. Previous classes Regression Regression –Linear regression –Multiple regression –Logistic regression.
Basic Statistics in Clinical Research Slides created from article by Augustine Onyeaghala (MSc, PhD, PGDQA, PGDCR, MSQA,
Overall agenda Part 1 and 2  Part 1: Basic statistical concepts and descriptive statistics summarizing and visualising data describing data -measures.
2004/10/07Faculty Participation in CAT...1 Faculty Participation in the Center for the Advancement of Teaching, Xavier University of Louisiana.
Simple Linear Regression
Analysis of Clinical Trials with Multiple Outcomes Changchun Xie, PhD Assistant Professor of Biostatistics Division of Biostatistics and Bioinformatics.
Epidemiology The Basics Only… Adapted with permission from a class presentation developed by Dr. Charles Lynch – University of Iowa, Iowa City.
Understanding Statistics
The Role of Statistical Methodology in Clinical Research – Shaping and Influencing Decision Making Frank Bretz Global Head – Statistical Methodology, Novartis.
Statistical Power and Sample Size Calculations Drug Development Statistics & Data Management July 2014 Cathryn Lewis Professor of Genetic Epidemiology.
Empowering Evidence: Basic Statistics June 3, 2015 Julian Wolfson, Ph.D. Division of Biostatistics School of Public Health.
Various topics Petter Mostad Overview Epidemiology Study types / data types Econometrics Time series data More about sampling –Estimation.
Decision-Theoretic Views on Switching Between Superiority and Non-Inferiority Testing. Peter Westfall Director, Center for Advanced Analytics and Business.
Introduction to Survival Analysis Utah State University January 28, 2008 Bill Welbourn.
4 Hypothesis & Testing. CHAPTER OUTLINE 4-1 STATISTICAL INFERENCE 4-2 POINT ESTIMATION 4-3 HYPOTHESIS TESTING Statistical Hypotheses Testing.
RevMan for Registrars Paul Glue, Psychological Medicine What is EBM? What is EBM? Different approaches/tools Different approaches/tools Systematic reviews.
All-or-None procedure: An outline Nanayaw Gyadu-Ankama Shoubhik Mondal Steven Cheng.
DSBS Discussion: Multiple Testing 28 May 2009 Discussion on Multiple Testing Prepared and presented by Lars Endahl.
1 Controlling False Positive Rate Due to Multiple Analyses Controlling False Positive Rate Due to Multiple Analyses Unstratified vs. Stratified Logrank.
Survival Analysis 1 Always be contented, be grateful, be understanding and be compassionate.
SCT The analysis of case cohort design in the presence of competing risks Melania Pintilie, Yan Bai, Lingsong Yun and David C. Hodgson Ontario Cancer.
Proof of Concept and Dose Estimation in Phase II Clinical Trials Bernhard Klingenberg Asst. Prof. of Statistics Williams College Slides, paper and R-code.
2006, Tianjin, China sf.ppt - Faragalli 1 Statistical Hypotheses and Methods in Clinical Trials with Active Control Non-inferiority Design Yong-Cheng.
Bayesian Approach For Clinical Trials Mark Chang, Ph.D. Executive Director Biostatistics and Data management AMAG Pharmaceuticals Inc.
Overview and Common Pitfalls in Statistics and How to Avoid Them
1 Chihiro HIROTSU Meisei (明星) University Estimating the dose response pattern via multiple decision processes.
Simulation Study for Longitudinal Data with Nonignorable Missing Data Rong Liu, PhD Candidate Dr. Ramakrishnan, Advisor Department of Biostatistics Virginia.
Love does not come by demanding from others, but it is a self initiation. Survival Analysis.
John W. Tukey’s Multiple Contributions to Statistics at Merck Joseph F. Heyse Merck Research Laboratories Third International Conference on Multiple Comparisons.
Strengthening Research Capabilities Professor John B. Kaneene DVM, MPH, PhD, FAES, FAVES Center for Comparative Epidemiology Michigan State University.
1 Bandit Thinkhamrop, PhD.(Statistics) Dept. of Biostatistics & Demography Faculty of Public Health Khon Kaen University Overview and Common Pitfalls in.
Stats Term Test 4 Solutions. c) d) An alternative solution is to use the probability mass function and.
1 Pulminiq™ Cyclosporine Inhalation Solution Pulmonary Drug Advisory Committee Meeting June 6, 2005 Statistical Evaluation Statistical Evaluation Jyoti.
Introduction to Biostatistics, Harvard Extension School, Fall, 2005 © Scott Evans, Ph.D.1 Sample Size and Power Considerations.
Joint Modelling of Accelerated Failure Time and Longitudinal Data By By Yi-Kuan Tseng Yi-Kuan Tseng Joint Work With Joint Work With Professor Jane-Ling.
Introduction to General Epidemiology (2) By: Dr. Khalid El Tohami.
Kelci J. Miclaus, PhD Advanced Analytics R&D Manager JMP Life Sciences
Sample size calculation Ahmed Hassouna, MD
Associations of Maternal Antidepressant Use During the First Trimester of Pregnancy With Preterm Birth, Small for Gestational Age, Autism Spectrum Disorder,
Lisa A. Weissfeld Professor and Associate Chair Dept. of Biostatistics
Multiple Endpoint Testing in Clinical Trials – Some Issues & Considerations Mohammad Huque, Ph.D. Division of Biometrics III/Office of Biostatistics/OPaSS/CDER/FDA.
Crucial Statistical Caveats for Percutaneous Valve Trials
Covering Principle to Address Multiplicity in Hypothesis Testing
David Edwards and Jesper Madsen Novo Nordisk
Medical Statistics Exam Technique and Coaching, Part 2 Richard Kay Statistical Consultant RK Statistics Ltd 22/09/2019.
Detecting Treatment by Biomarker Interaction with Binary Endpoints
Yu Du, PhD Research Scientist Eli Lilly and Company
Logical Inference on Treatment Efficacy When Subgroups Exist
Incorporating the sample correlation between two test statistics to adjust the critical points for the control of type-1 error Dror Rom and Jaclyn McTague.
Presentation transcript:

Faculty Research Interest Seminar Series Graduate School of Public Health, UNIVERSITY of PITTSBURGH Methodological Research and Collaboration Lan Kong Assistant professor Department of Biostatistics October 20, 2015

Dept of Biostatistics, GSPH, UNIVERSITY of PITTSBRGH Outline Introduction Methodological Research Survival analysis Clinical trials Collaboration Projects Motivated problems

Dept of Biostatistics, GSPH, UNIVERSITY of PITTSBRGH Introduction Joined the Biostat dept in August 2003 PhD in Biostat from UNC-Chapel Hill In collaboration with critical care medicine dept. On doctoral exam committee Courses intend to teach: survival analysis, advanced categorical data analysis, or estimating equation method.

Dept of Biostatistics, GSPH, UNIVERSITY of PITTSBRGH Methodological research Survival analysis Study design: case-cohort Model: semiparametric transformation models and accelerated failure time model. Approach: estimating equation method, inverse of probability weighting technique Statistical theory: U-statistics, finite population sampling, martingales, empirical/stochastic process

Dept of Biostatistics, GSPH, UNIVERSITY of PITTSBRGH Case-cohort design (Prentice, 1986) Subcohort Full cohort Complete data available for Subcohort + Additional Cases outside the subcohort Full cohort Failures/cases

Dept of Biostatistics, GSPH, UNIVERSITY of PITTSBRGH Semiparametric Survival Models Cox model λ (t)= λ 0 (t)exp(β’Z), λ 0 (t) unspecified Transformation models h (T)= -β’Z+ε OR g{S z (t)}=h(t)+ β’Z h unknown, ε has known CDF F(.), g -1 =1-F. Accelerated failure time model log (T)= -β’Z+ε, ε has unspecified CDF.

Dept of Biostatistics, GSPH, UNIVERSITY of PITTSBRGH Methodological Research (cont.) Clinical trials Problem: Multiplicity issues Example: Multi-dose clinical trials--correlations among multiple comparisons Statistical concerns: familywise Type I error and power

Dept of Biostatistics, GSPH, UNIVERSITY of PITTSBRGH Family-Wise Error (FWE) Probability that at least one hypothesis is incorrectly declared significant. Strongly control of FWE: FWE is protected for any composite null hypothesis Closed testing procedures strongly control the FWE

Dept of Biostatistics, GSPH, UNIVERSITY of PITTSBRGH Multiple testing procedures Analysis strategies: Perform a sequence of tests in a pre-specified order through the closed testing principle : 1. Global assessment of any dose effect 2. Comparisons of doses to Placebo 3. Other comparisons among doses Manage multiplicity within the respective steps by Hochberg method (BKA, 1988), closed testing procedure.

Dept of Biostatistics, GSPH, UNIVERSITY of PITTSBRGH Vaccine trials Problem: Inferiority/Equivalence assessment Multiplicity due to multiple endpoints (immune responses) Statistical concerns: How correlations among endpoints affect study design of inferiority/EQ trials (power, sample size)?

Dept of Biostatistics, GSPH, UNIVERSITY of PITTSBRGH -K 0 -K 0 K T-C H 0 (inf) H 1 (noninf) H 0 (noneq) H 1 (eq) H 0 (noneq) 0 T-C H 0 (inf) H 1 (sup) Hypotheses T: treatment group, C: control group

Dept of Biostatistics, GSPH, UNIVERSITY of PITTSBRGH Further questions of interest How to handle multiple endpoints in multi-dose clinical trials? How to simultaneously assess inferiority/EQ on some endpoints and superiority on the others?

Dept of Biostatistics, GSPH, UNIVERSITY of PITTSBRGH Collaboration Projects mainly involved: Genetic and inflammatory markers of Sepsis (GenIMS) Economic Analysis of the Pulmonary Artery Catheter Use (EA-PAC) Prolonged Outcomes of Nitric Oxide for Ventilated Premature Babies (PRONOX)

Dept of Biostatistics, GSPH, UNIVERSITY of PITTSBRGH Statistical problems motivated from collaborative projects

Dept of Biostatistics, GSPH, UNIVERSITY of PITTSBRGH Genetic data Explore how the candidate markers interactively affect the outcome (Selection of subset from a list of candidate genetic markers) Statistical learning method Pattern recognition approach Haplotype analysis for survival data to accommodate missing genotypes, case- cohort design

Dept of Biostatistics, GSPH, UNIVERSITY of PITTSBRGH Missing and/or truncated data Examples: inflammatory marker data are below detectable limit, the measurement on the severity of sepsis are heavily missing Longitudinal analysis of truncated inflammatory marker (extension of Tobit model) Jointly modeling several truncated inflammatory markers Testing whether the missing is informative in the non-monotone missing pattern Jointly modeling the longitudinal outcome and longitudinal covariates

Dept of Biostatistics, GSPH, UNIVERSITY of PITTSBRGH Quality of Life and Cost data Various types of outcomes: survival data, cost data, quality of life data. Informative censoring Modeling quality adjusted survival Jointly modeling QOL with survival data Cost-effective analysis in presence of repeated measures and missing data

Dept of Biostatistics, GSPH, UNIVERSITY of PITTSBRGH Related papers Kong L, Cai J, Sen PK. Weighted estimating equations for semiparametric transformation models with censored data from a case-cohort design. Biometrika 2004; 91(2): Kong L, Cai J, Sen PK. Asymptotic results for fitting semiparametric transformation models to failure time data from a case-cohort design. Statistica Sinica 2004, in press. Kong L. Analysis of case-cohort data with accelerated failure time model, in preparation

Dept of Biostatistics, GSPH, UNIVERSITY of PITTSBRGH Related papers (cont.) Kong L, Kohberger R, Koch G. Type I error and power in non-inferiority/equivalence trials with correlated multiple endpoints: an example from vaccine development trials. Journal of Biopharmaceutical Statistics 2004; 14(4): Kong L, Koch G, Liu T, Wang H. Performance of some multiple testing procedures to compare three doses of a test drug and placebo. Pharmaceutical Statistics 2004, in press. Kong L, Kohberger R, Koch G. Equivalence/non- inferiority assessment on multiple proportion outcomes. In preparation.